The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...

Mitsubishi Chemical Holdings ( (JP:4188) ) has issued an announcement.

Repirinast is the Company's lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

Camp HLC provides an unforgettable experience for children, young adults, and families who have or had a loved one living with ALS.

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

The Japanese pharma company files complaint against Lupin Pharmaceuticals | Suit alleges patent infringement over the company ...